Drug allergy epidemiology and demographics

Revision as of 21:46, 13 February 2013 by Kalsang Dolma (talk | contribs)
Jump to: navigation, search

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Charmaine Patel, M.D. [2]

Drug Allergy

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Drug allergy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Drug allergy epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Drug allergy epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Drug allergy epidemiology and demographics

CDC on Drug allergy epidemiology and demographics

Drug allergy epidemiology and demographics in the news

Blogs on Drug allergy epidemiology and demographics

Directions to Hospitals Treating Drug allergy

Risk calculators and risk factors for Drug allergy epidemiology and demographics

Overview

Adverse drug reactions may occur in up to 10% of the worldwide population, and also affect up to 20% of patients who are hospitalized. Of all the cases of fatalities caused by anaphylaxis, drugs may be responsible for 20% of the deaths. The incidence of toxic epidermal necrolysis is about 0.4-1.2 cases per million in a year.

References



Linked-in.jpg